30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Strategic Initiatives

Bone Biologics Signs Option to License Nell-1 Bone Growth Factor for Use in Osteoporosis -

Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.

Bone Biologics is presently funding the development of a Nell-1-based bone graft substitute for spinal fusion, also under exclusive license from UCLA. Nell-1 has demonstrated an ability to target bone formation with a high degree of safety, suggesting it to be an attractive treatment modality vs. other bone growth factors and implanted devices.

Sources: Bone Biologics Corporation, ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.